A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 230-235

  Emsley, Robin ^a   Chiliza, Bonginkosi ^a   Asmal, Laila ^a   du Plessis, Stefan ^a   Phahladira, Lebogang ^a   van Niekerk, Evette ^a   van Rensburg, Susan J ^a   Harvey, Brian H ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Antioxidant; Omega 3; Placebo; Relapse prevention; Schizophrenia

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; PLACEBO; THIOCTIC ACID; ANTIOXIDANT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MALE; MENTAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; DRUG COMBINATION; KAPLAN MEIER METHOD; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SECONDARY PREVENTION; TIME;

ADULT; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SECONDARY PREVENTION; THIOCTIC ACID; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906937073     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.06.004     Document Type: Article

References (31)

1. Addington D., Addington J. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry 1993, 163:S39-S44.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, Washington, D.C. 4th edn.
3. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
4. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
5. Berger G.E., Proffitt T.M., McConchie M., Yuen H., Wood S.J., Amminger G.P., Brewer W., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry 2007, 68:1867-1875.
6. Boonstra G., Burger H., Grobbee D.E., Kahn R.S. Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int. J. Psychiatry Clin. Pract. 2011, 15:128-134.
7. Chiliza B., Ojagbemi A., Esan O., Asmal L., Oosthuizen P., Kidd M., Gureje O., Emsley R. Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting. Early Interv. Psychiatry 2014, (in press). 10.1111/eip.12141.
8. Chouinard G., Margolese H.C. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr. Res. 2005, 76:247-265.
9. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002, 346(1):16-22.
10. Emsley R., Fleischhacker W.W. Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?. Schizophr. Res. 2013, 150:427-433.
11. Emsley R., Myburgh C., Oosthuizen P., van Rensburg S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 2002, 159:1596-1598.
12. Emsley R., Oosthuizen P., van Rensburg S.J. Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs 2003, 17:1081-1091.
13. Emsley R., Niehaus D.J., Koen L., Oosthuizen P.P., Turner H.J., Carey P., van Rensburg S.J., Maritz J.S., Murck H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr. Res. 2006, 84:112-120.
14. Emsley R., Niehaus D.J., Oosthuizen P.P., Koen L., Ascott-Evans B., Chiliza B., van Rensburg S.J., Smit R.M. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Res. 2008, 161:284-291.
15. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001, 158:2071-2074.
16. First M.B., Spitzer R.L.G.M., Williams L.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P) 1994, Biometrics Research, New York State Psychiatric Institute, New York. 2nd.
17. Fusar-Poli P., Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J. Clin. Psychopharmacol. 2012, 32:179-185.
18. Green M.F., Kern R.S., Heaton R.K. Longitudinal relationships of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72:41-55.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. ADM 76-338 1976, 217-222. US Department of Health, Education and Welfare, Rockville, Md.
20. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998, 30:193-208.
21. Kay S.R., Fizbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987, 13:261-267.
22. Mahadik S.P., Pillai A., Joshi S., Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry 2006, 18:119-131.
23. Miller T.J., McGlashan T.H., Woods S.W., Stein K., Driesen N., Corcoran C.M., Hoffman R., Davidson L. Symptom assessment in schizophrenic prodromal states. Psychiatr. Q. 1999, 70:273-287.
24. Packer L. The metabolic antioxidant. Free Radic. Biol. Med. 1996, 20(4):625-626.
25. Peet M., Horrobin D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002, 36:7-18.
26. Peet M., Brind J., Ramchand C.N., Shah S., Vankar G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001, 49:243-251.
27. Petersen Shay K., Moreau R.F., Smith E.J., Hagen T.M. Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life 2008, 60(6):362-367.
28. Seybolt S.E. Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia?. Med. Hypotheses 2010, 75(6):572-575.
29. Takeuchi H., Suzuki T., Uchida H., Watanabe K., Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr. Res. 2012, 134:219-225.
30. The WHOQOL Group Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol. Med. 1998, 28(3):551-558.
31. Zipursky R.B., Menezes N.M., Streiner D.L. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr. Res. 2014, 152:408-414.